Iovance Biotherapeutics, Inc.
IOVA
Helyezés a részvények között
#2768
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Részvényárfolyam
$14.95
Piaci kapitalizáció
$6.77B
Változás (1 nap)
0.57%
Változás (1 év)
558.37%
Ország
US
Kereskedés Iovance Biotherapeutics, Inc. (IOVA)
Kategória
Healthcare
Iovance Biotherapeutics, Inc. (IOVA) P/B aránya
P/B arány ekkor: October 2026 TTM: 8.69
Iovance Biotherapeutics, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 8.69. 2023 végén ez az arány 3.27 volt.
P/B arány története a(z) Iovance Biotherapeutics, Inc. esetén 2008 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 8.69 | 187.79% |
| 2024 | 3.02 | -7.66% |
| 2023 | 3.27 | 60.54% |
| 2022 | 2.04 | -56.76% |
| 2021 | 4.71 | -51.81% |
| 2020 | 9.77 | -15.09% |
| 2019 | 11.51 | 523.36% |
| 2018 | 1.85 | -48.53% |
| 2017 | 3.59 | 55.91% |
| 2016 | 2.30 | -30.18% |
| 2015 | 3.30 | -24.84% |
| 2014 | 4.38 | -24.70% |
| 2013 | 5.82 | -475.21% |
| 2012 | -1.55 | -73.87% |
| 2011 | -5.94 | -104.65% |
| 2010 | 127.82 | -101.69% |
| 2009 | -7.55K | -112.90% |
| 2008 | 58.49K | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | -28.08% |
US
|
|
| 13.2547 | 52.51% |
US
|
|
| 4.208 | -51.58% |
AU
|
|
| 6.1824 | -28.87% |
NL
|
|
| - | - |
CH
|
